Learn more

HANGZHOU CONVERD CO LTD

Overview
  • Total Patents
    36
  • GoodIP Patent Rank
    43,270
  • Filing trend
    ⇧ 214.0%
About

HANGZHOU CONVERD CO LTD has a total of 36 patent applications. It increased the IP activity by 214.0%. Its first patent ever was published in 2016. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are APOLLON INC, SEMENTIS LTD and INTROGEN THERAPEUTICS INC.

Patent filings in countries

World map showing HANGZHOU CONVERD CO LTDs patent filings in countries

Patent filings per year

Chart showing HANGZHOU CONVERD CO LTDs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Hu Fang 26
#2 Zhao Ronghua 25
#3 Chen Lin 21
#4 Fu Jin 12
#5 Kang Sanmao 8
#6 Sheng Jipo 7
#7 Zhang Rong 6
#8 Wang Tingting 6
#9 Qin Yun 6
#10 Hou Yafei 6

Latest patents

Publication Filing date Title
WO2020192684A1 Therapeutic agent containing isolated recombinant oncolytic adenovirus and immune cells and use therefor
CN112143693A Method for producing virus and harvesting solution composition
CN110857319A Isolated T cell receptor, modified cell thereof, encoding nucleic acid and application thereof
CN109776671A Cell, code nucleic acid, expression vector, preparation method, pharmaceutical composition and the application of isolated T cell receptor, its modification
CN109576231A Isolated recombination oncolytic adenovirus, pharmaceutical composition and its purposes in the drug for the treatment of tumour and/or cancer
CN109554353A Isolated recombination oncolytic poxvirus, pharmaceutical composition and its purposes in the drug for the treatment of tumour and/or cancer
CN108338994A Application of the oncolytic virus as the immunostimulant for treating tumour and/or cancer
CN108261426A Pharmaceutical composition and its application in the drug for the treatment of tumour and/or cancer
CN108182346A Predict method for building up and its application of the siRNA for the machine learning model of the toxicity of certain class cell
US2016250292A1 In vivo individualized systemic immunotherapeutic method and device